Skip to content

Azzly ® - Behavioral Health Practice Management Software

FacebookLinkedinX-twitterYoutubeSpotifyInstagram

Who We Serve
Features
Pricing Plans
Expert Services
- Software Implementation Plan
- Integrated Billing
Resources
(772) 567-0206

Who We Serve
Features
Pricing Plans
Expert Services
- Software Implementation Plan
- Integrated Billing
Resources
(772) 567-0206

Who We Serve
Features
Pricing Plans
Expert Services
- Software Implementation Plan
- Integrated Billing
Resources
(772) 567-0206

Who We Serve
Features
Pricing Plans
Expert Services
- Software Implementation Plan
- Integrated Billing
Resources
(772) 567-0206

Tag: brexanolone

Questions To Ask Before Purchasing an EMR or EHR

Industry News

FDA Approves Postpartum Depression Drug Zulresso, But Concerns Arise Over Cost

In mid-March, the FDA approved the postpartum depression drug brexanolone,

April 2, 2019 No Comments

AZZLY®: Behavioral Health EHR & EMR Software

Orlando, FL/Vero Beach, FL

1 (888) 400-3201

Useful Links

Programs We Serve
Software
Pricing Plan
Expert Services
Resources
The Team
Login
Contact

Who We Serve

Mental Health
Community-Based Outpatient
Inpatient Psychiatric Rehabilitation
Residential Treatment
Medication Management
Eating Disorder
Addiction Treatment
Medication Assisted Treatment
Abstinence-Based Treatment
Detox Inpatient-Outpatient
Office-Based Opioid Treatment (OBOT)
RCM Healthcare Services

Solutions

EMR/EHR
Outcome Measurement Tools
Billing/RCM
Analytics
Mobility
Learning Services
Patient Engagement
Consulting
Telehealth

LinkedinFacebookX-twitterInstagramYoutubeSpotify

American Owned & Operated. © Copyright 2025 AZZLY. All rights reserved | Powered by Visionation

| Home | Sitemap | Privacy Policy | Services Agreement | 1 (888) 400-3201 | Orlando, FL/Vero Beach, FL

Scroll to Top

Postpartum Depression Drug Zulresso: FDA Approval and Cost Concerns

Recently, the FDA approved the use of brexanolone, now marketed as Zulresso, for the treatment of postpartum depression. This approval marks a significant step forward in addressing a condition that affects many new mothers. The drug has shown promising results in clinical trials, offering relief for women struggling with this debilitating form of depression.

However, concerns have been raised regarding the cost of Zulresso. With a price tag of around $34,000 for a single treatment course, many are worried about the accessibility and affordability of this drug. It remains to be seen how insurance coverage and other financial assistance programs will impact the availability of Zulresso for those in need.

Postpartum Depression Drug Zulresso: FDA Approval and Cost Concerns

Recently, the FDA approved the use of brexanolone, now marketed as Zulresso, for the treatment of postpartum depression. This approval marks a significant step forward in addressing a condition that affects many new mothers. The drug has shown promising results in clinical trials, offering relief for women struggling with this debilitating form of depression.

However, concerns have been raised regarding the cost of Zulresso. With a price tag of around $34,000 for a single treatment course, many are worried about the accessibility and affordability of this drug. It remains to be seen how insurance coverage and other financial assistance programs will impact the availability of Zulresso for those in need.